PPIDT00133
Drug Information
| Name | Abaloparatide |
|---|---|
| Sequence | AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA |
| DrugBank_ID | DB05084 |
| Type | biotech |
| Indication | Abaloparatide is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) [L740,L44737] or patients who have failed or are intolerant to other available osteoporosis therapy.[L740] In postmenopausal women with osteoporosis, abaloparatide reduces the risk of vertebral and nonvertebral fractures.[L740] Abaloparatide is also indicated to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy.[L740] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
80 mcg
|
| Injection, solution | Subcutaneous |
80 ug/dose
|
| Injection, solution | Subcutaneous |
80 mcg/40mcl
|
| Injection, solution | Subcutaneous |
3.12 mg/1.56mL
|